Compare STAA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | CGEM |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.9M | 794.7M |
| IPO Year | 1995 | 2020 |
| Metric | STAA | CGEM |
|---|---|---|
| Price | $18.63 | $13.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $22.19 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 1.3M | 773.4K |
| Earning Date | 03-03-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $239,442,000.00 | N/A |
| Revenue This Year | $27.04 | N/A |
| Revenue Next Year | $7.27 | $79.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.69 | $5.68 |
| 52 Week High | $30.81 | $16.74 |
| Indicator | STAA | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 49.95 |
| Support Level | $17.13 | $11.43 |
| Resistance Level | $19.44 | $16.74 |
| Average True Range (ATR) | 0.92 | 0.83 |
| MACD | 0.12 | -0.16 |
| Stochastic Oscillator | 71.74 | 32.74 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.